ID   MKPL-1
AC   CVCL_2116
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473446
DR   Cosmic; 787452
DR   Cosmic; 975270
DR   Cosmic; 1012091
DR   Cosmic; 1281328
DR   Cosmic; 2306219
DR   DSMZ; ACC-697
DR   DSMZCellDive; ACC-697
DR   JCRB; JCRB1325
DR   JCRB; NIHS0536
DR   Wikidata; Q54905835
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1602796;
RX   PubMed=16408098;
RX   PubMed=17360941;
RX   PubMed=31160637;
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Japanese.
CC   Doubling time: 30 hours (PubMed=1602796); ~50-60 hours (DSMZ=ACC-697).
CC   HLA typing: A*24:02:01,31:01:02; B*07:02:01,56:01:01; C*04:01:01,07:02:01 (DSMZCellDive=ACC-697).
CC   Sequence variation: Gene fusion; HGNC; 2433; CSF1R + HGNC; 9903; RBM6; Name(s)=RBM6-CSF1R (PubMed=17360941).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: JCRB; NIHS0536; true.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): DSMZ; JCRB
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 8,11
ST   D16S539: 9
ST   D18S51: 14
ST   D19S433: 14,14.2
ST   D21S11: 29,31.2
ST   D2S1338: 19,23
ST   D3S1358: 16,17
ST   D5S818: 11,12
ST   D7S820: 11
ST   D8S1179: 13
ST   FGA: 19,24
ST   Penta D: 9,10
ST   Penta E: 5,17
ST   TH01: 8,9.3
ST   TPOX: 10,11
ST   vWA: 17,18
DI   NCIt; C7965; Adult acute megakaryoblastic leukemia
DI   ORDO; Orphanet_518; Acute megakaryoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   66Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 20
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1602796;
RA   Takeuchi S., Sugito S., Uemura Y., Miyagi T., Kubonishi I.,
RA   Taguchi H., Enzan H., Ohtsuki Y., Miyoshi I.;
RT   "Acute megakaryoblastic leukemia: establishment of a new cell line
RT   (MKPL-1) in vitro and in vivo.";
RL   Leukemia 6:588-594(1992).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=17360941; DOI=10.1182/blood-2006-10-052282;
RA   Gu T.-L., Mercher T., Tyner J.W., Goss V.L., Walters D.K.,
RA   Cornejo M.G., Reeves C., Popova L., Lee K., Heinrich M.C., Rush J.,
RA   Daibata M., Miyoshi I., Gilliland D.G., Druker B.J.,
RA   Polakiewicz R.D.;
RT   "A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia.";
RL   Blood 110:323-333(2007).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//